Safety and tolerability of sublingual immunotherapy in clinical trials and real life

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 656-662

  Senna, Gianenrico ^a   Caminati, Marco ^a   Canonica, Giorgio Walter ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adherence; Safety; Sublingual immunotherapy; Tolerability

Indexed keywords

ADRENALIN;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ASTHMA; BLOOD PRESSURE; CLINICAL EVALUATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD ALLERGY; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTENSION; MEDICATION COMPLIANCE; PATIENT ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TONGUE SWELLING; TREATMENT WITHDRAWAL; URTICARIA; VIRAL PHARYNGITIS; VITAL SIGN; WHEEZING;

ADULT; ASTHMA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; SUBLINGUAL IMMUNOTHERAPY;

EID: 84889882301     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000007     Document Type: Review

References (48)

1. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjuntivits and asthma. J Am Med Assoc 2013; 309:1278-1288. To our knowledge, the last published comprehensive review providing an overview into efficacy, safety and tolerability of sublingual immunotherapy for allergic respiratory diseases in children and adults.
2. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64:1-59.
3. Sikora JM, Takersley MS, ACAAI Immunotherapy and Diagnostic Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States. Ann Allergy Asthma Immunol 2013; 110: 194-197.
4. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:569-574.
5. Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288-298.
6. Nayak AS, Atiee GJ, Dige E, et al. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc 2012; 33:404-410.
7. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327-1334.
8. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: A double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 2013; 43:242-248.
9. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013; 131:1342-1349.
10. Wang DH, Chen L, Cheng L, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope 2013; 123:1334-1340.
11. Aydogan M, Eifan AO, Keles S, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: A double-blind-placebo-controlled randomised trial. Respir Med 2013; 107:1322-1329.
12. Blaiss M, Maloney J, Nolte H. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64-71.
13. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127:72-80.
14. Bousquet PJ, Brozek J, Bachert C, et al. The CONSORT statement checklist in allergen-specific immunotherapy: A GA2LEN paper. Allergy 2009; 64: 1737-1745.
15. Casale TB, Canonica GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124:666-670.
16. Medical Dictionary for Regulatory Activities (MedDRA). Maintenance support services and organization. http://www.meddramsso.com/. [Accessed May 2013]
17. Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013; 132:93-98. A WAO Task Force proposes here the first grading system of SLIT-related local side effects, on the basis of the available literature and the postmarketing surveillance data.
18. Di Rienzo V, Pagani A, Parmiani S, et al. Postmarketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999; 54:1110-1113.
19. Lombardi C, Gargioni S, Melchiorre A, Passalacqua G. Safety of sublingual immunotherapy in adults: A post marketing surveillance study. Allergy 2001; 56:889-892.
20. Pajno GB, Peroni DG, Vita D, et al. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5:777-781.
21. Fiocchi A, Pajno G, La Grutta S, et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95:254-258.
22. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: A post marketing survey. Allergol Immunopathol 2004; 32:76-81.
23. Calderon MA, Simons FER, Malling H-J, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67:302-311. This recent review discusses and provides an interesting insight into local and systemic adverse effects of allergen immunotherapy and focuses on their management. It also highlights potential risk factors associated with SLIT and SCIT-related anaphylaxis.
24. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy 2011; 41:1247-1255.
25. Calderó n MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Cin Immunol 2011; 127:30-38.
26. Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force on 'dose-response relationship in allergenspecific immunotherapy'. Allergy 2011; 66:1345-1359.
27. Gidaro GB, Frati F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: An analysis of published studies. Clin Exp Allergy 2005; 35:565-571.
28. Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012; 129:929-934.
29. Agostinis F, Tellarini R, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005; 60:133.
30. Di Rienzo V, Minelli M, Musarra A, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35:560-564.
31. Agostinis F, Foglia C, Landi M, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008; 63:1637-1639.
32. Lombardi C, Gargioni S, Cottini M, et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008; 63:675-676.
33. Rodriguez-Perez N, Ambriz-Moreno AJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304-310.
34. De Castro G, Zicai AM, Indinnimeo L, et al. Efficacy of sublilngual immunotherapy on allergic asthma in children's real life. Eur Rev Med Pharmacol Sci 2013; 17:2225-2231.
35. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236-1237.
36. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235.
37. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2008; 62:567-568.
38. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63:374.
39. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immuno-therapy with grass pollen tablet. Allergy 2009; 64:963-964.
40. Buyukozturk S, Gelincik A, Ozşeker F, et al. Latex sublingual immunotherapy: can its safety be predicted? Ann Allergy Asthma Immunol 2010; 104:339-342.
41. Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol Madr 2012; 17:263-267.
42. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131:1288-1296.
43. Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol 2012; 23:401.
44. Senna G, Ridolo E, Calderon M, et al. Evidence of adherence to immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:544-548.
45. Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012; 23:688-689.
46. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: A pragmatic approach. Allergy 2013. [Epub ahead of print]
47. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013; 43:22-28.
48. Senna G, Lombardi C, Passalacqua G, Canonica GW. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturer's point of view. J Allergy Clin Immunol 2010; 126:668-669.